Cargando…
Perspectives and Future Directions of Anticoagulant Therapy in Coronary Artery Disease Patients
Antiplatelet agents are routinely used to treat patients with chronic atherosclerotic coronary artery disease. Treatment with the addition of a low dose of rivaroxaban as dual-pathway inhibition (DPI) decreases ischaemic events at the expense of increased bleeding. At present, the balance between th...
Autores principales: | Komiyama, Maki, Dan, Gheorghe-Andrei, Hasegawa, Koji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radcliffe Cardiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316355/ https://www.ncbi.nlm.nih.gov/pubmed/37405346 http://dx.doi.org/10.15420/ecr.2022.66 |
Ejemplares similares
-
Will Direct Oral Anticoagulants Have a Chance in Prosthetic Valves?
por: Abdelnabi, Mahmoud, et al.
Publicado: (2020) -
AF in Cancer Patients: A Different Need for Anticoagulation?
por: Sanz, Ana Pardo, et al.
Publicado: (2019) -
Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy
por: Camarero, Tamara García, et al.
Publicado: (2020) -
Validating the Prognostic Utility of the ABCD-GENE Score in Asian Patients with Acute Coronary Syndrome Patients on Clopidogrel
por: Tan, Cheng Keat, et al.
Publicado: (2023) -
Carotid artery intima media thickness can predict the response to phosphodiesterase 5 inhibitors in patients with moderate erectile dysfunction
por: Kilic, Metin, et al.
Publicado: (2023)